“People with advanced alveolar soft part sarcoma (ASPS), a rare cancer, appear to benefit from a type of immunotherapy called an immune checkpoint inhibitor, according to results from a small clinical trial.
Few treatments tested in the past in people with ASPS have shown any effect. The exception has been a class of drugs called tyrosine kinase inhibitors (TKIs), which include sorafenib (Nexavar) and cediranib (Recentin). Although some patients’ tumors shrink following treatment with these drugs, most cancers eventually stop responding to treatment.
In the new NCI-led trial, tumors either shrank or stopped growing following treatment with the checkpoint inhibitor atezolizumab (Tecentriq).”
““For patients whose disease has metastasized, it’s exciting that there may now be a whole new class of drugs that have [anticancer] activity,” said Scott Schuetze, M.D., Ph.D., who specializes in treating sarcomas at the University of Michigan but was not involved in the study.
The trial results were presented November 16 at the 2018 annual meeting of the Connective Tissue Oncology SocietyExit Disclaimer (CTOS).“”
https://www.cancer.gov/news-events/canc ... coma-trial
Immunotherapy Effective in Alveolar Soft Part Sarcoma
Re: Immunotherapy Effective in Alveolar Soft Part Sarcoma
It is a good supportive article but the CTOS stopped openly publish its abstracts few years ago, so we do not have an access unless some of our oncologists attended it.
Olga
Re: Immunotherapy Effective in Alveolar Soft Part Sarcoma
It looks that way Olga
I guess little baby steps with info we are given .:)
Especially to ICIS?
“TKIs and immunotherapy hold promise for alveolar soft part sarcoma“
https://www.mdedge.com/sarcomajournal/a ... -soft-part
I get the feeling with Joshua’s larger tumors in his lungs and disseminated disease ( liver , kidney and lower pelvic)
The TKI( sutent ) and the liver ablation followed by the Opdivo even a year later than the ablation/7 months from sutent, was a good combination to aid in Joshua’s success thus far .
I guess little baby steps with info we are given .:)
Especially to ICIS?
“TKIs and immunotherapy hold promise for alveolar soft part sarcoma“
https://www.mdedge.com/sarcomajournal/a ... -soft-part
I get the feeling with Joshua’s larger tumors in his lungs and disseminated disease ( liver , kidney and lower pelvic)
The TKI( sutent ) and the liver ablation followed by the Opdivo even a year later than the ablation/7 months from sutent, was a good combination to aid in Joshua’s success thus far .
Debbie
Re: Immunotherapy Effective in Alveolar Soft Part Sarcoma
Was also remembering Josh was on propranolol for tremors , during this regiment of ablations and sutent 2015 usage .
7 months prior to Opdivo (2016)and it’s subsequent success until late 2019.
viewtopic.php?f=3&t=1674
7 months prior to Opdivo (2016)and it’s subsequent success until late 2019.
viewtopic.php?f=3&t=1674
Debbie